Citizens JMP Keeps Hold Rating on Globus Medical Despite 33.61% Upside Potential

Citizens JMP analyst David Turkaly reiterated a Hold rating on Globus Medical (GMED) with a price target of $65.00. The analyst has a success rate of 38.95% and an average return of -5.0%. The consensus rating is Moderate Buy with a price target of $81.73, representing a 33.61% upside. Globus Medical has a one-year high of $94.93 and a one-year low of $51.79.

Citizens JMP analyst David Turkaly reiterated a Hold rating on Globus Medical (GMED) with a price target of $65.00. The analyst has a success rate of 38.95% and an average return of -5.0%. The consensus rating is Moderate Buy with a price target of $81.73, representing a 33.61% upside. Globus Medical has a one-year high of $94.93 and a one-year low of $51.79 [1].

In the past three months, 14 analysts have given ratings to GMED, with 9 analysts rating it as a Moderate Buy, 5 as a Buy, and 0 as a Sell. The average price target is $81.73, with a high forecast of $106.00 and a low forecast of $65.00. The highest price target is $106.00, and the lowest is $65.00. The average price target represents a 35.65% change from the last price of $60.25 [1].

Analysts have shown varying opinions on GMED's stock. While some analysts like Morgan Stanley and Barclays have reiterated their Buy ratings, others such as Needham and Oppenheimer have maintained Hold ratings. The recent earnings report of Nevro, a company acquired by GMED, showed better-than-expected results, with revenue of $95 million and operating income of -$5 million. This has led some analysts to believe in potential upside for GMED [1].

The stock has shown volatility in the past year, reaching a high of $94.93 and a low of $51.79. The current market conditions and the company's performance in the healthcare sector will continue to influence the stock's price [1].

References:
[1] https://www.tipranks.com/stocks/gmed/forecast